|
gptkbp:instanceOf
|
gptkb:drug
antiviral drug
|
|
gptkbp:administeredBy
|
gptkb:ritonavir
ombitasvir
paritaprevir
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
|
gptkbp:brand
|
Exviera
Viekira Pak (in combination)
|
|
gptkbp:CASNumber
|
1132935-63-7
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:AbbVie
|
|
gptkbp:drugClass
|
direct-acting antiviral
|
|
gptkbp:eliminationHalfLife
|
5.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
QXWZOBLZJGMJDC-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C26H27N3O4
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(C=C1)C2=NC(=NC(=N2)C3=CC=CC=C3)C(=O)N4CCOCC4)C5=CC=CC=C5O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dasabuvir
|
|
gptkbp:indication
|
gptkb:chronic_hepatitis_C_genotype_1
|
|
gptkbp:KEGGID
|
D10413
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
gptkb:NS5B_polymerase_inhibitor
|
|
gptkbp:metabolism
|
liver (CYP2C8, CYP3A4)
|
|
gptkbp:molecularWeight
|
445.51 g/mol
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
N (US)
|
|
gptkbp:PubChem_CID
|
28536938
CHEMBL2105758
46216216
DB09183
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
pruritus
insomnia
|
|
gptkbp:target
|
gptkb:HCV_NS5B_polymerase
|
|
gptkbp:UNII
|
6J8OL8451O
|
|
gptkbp:usedFor
|
treatment of hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:NS5B_polymerase_inhibitor
|
|
gptkbp:bfsLayer
|
7
|